Access to anti-retroviral drugs, male in Cambodia

Cambodia: Access to anti-retroviral drugs, male was 96.0% in 2024. ◆ Volatile

Latest (2024)
96.0%
Change on year
up 5.5%
World rank
3rd
of 141 countries
All-time high
96.0%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, male in Cambodia, 2000–2024

0204060801002000201220242000: 0 %2001: 0 %2002: 1 %2003: 3 %2004: 8 %2005: 14 %2006: 24 %2007: 31 %2008: 38 %2009: 45 %2010: 50 %2011: 53 %2012: 56 %2013: 58 %2014: 60 %2015: 63 %2016: 66 %2017: 68 %2018: 73 %2019: 77 %2020: 80 %2021: 81 %2022: 85 %2023: 91 %2024: 96 %

Source: UNAIDS estimates. Measured in %.

Analysis

The most recent figure for access to anti-retroviral drugs, male in Cambodia is 96.0%, measured in 2024. That is the highest value across all 25 years on record.

The figure is up 5.5% on the previous year and up 60.0% over ten years.

Over the whole period, access to anti-retroviral drugs, male in Cambodia peaked at 96.0% in 2024 and was at its lowest, 0.0%, in 2000.

Cambodia ranks 3rd of 141 countries on this measure, in the top 10%.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, male in Cambodia, year by year

Annual values for Access to anti-retroviral drugs, male (%) in Cambodia, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 1.0%
2003 3.0% +200.0%
2004 8.0% +166.7%
2005 14.0% +75.0%
2006 24.0% +71.4%
2007 31.0% +29.2%
2008 38.0% +22.6%
2009 45.0% +18.4%
2010 50.0% +11.1%
2011 53.0% +6.0%
2012 56.0% +5.7%
2013 58.0% +3.6%
2014 60.0% +3.4%
2015 63.0% +5.0%
2016 66.0% +4.8%
2017 68.0% +3.0%
2018 73.0% +7.4%
2019 77.0% +5.5%
2020 80.0% +3.9%
2021 81.0% +1.2%
2022 85.0% +4.9%
2023 91.0% +7.1%
2024 96.0% +5.5%

Averages by decade

DecadeAverage LowestHighest Years
2000s 16.4% 0.0% 45.0% 10
2010s 62.4% 50.0% 77.0% 10
2020s 86.6% 80.0% 96.0% 5

Countries ranked near Cambodia

  1. 1 Comoros 98.0% compare
  2. 2 Mauritania 97.0% compare
  3. 4 Rwanda 95.0% compare
  4. 4 Sweden 95.0% compare
  5. 4 Zambia 95.0% compare

See the full ranking of 160 places →

More gender data for Cambodia

All data for Cambodia →

Frequently asked questions

What is access to anti-retroviral drugs, male in Cambodia?
Access to anti-retroviral drugs, male in Cambodia was 96.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, male recorded in Cambodia?
The highest recorded value was 96.0% in 2024.
What is the lowest access to anti-retroviral drugs, male recorded in Cambodia?
The lowest recorded value was 0.0% in 2000.
How does Cambodia rank for access to anti-retroviral drugs, male?
Cambodia ranks 3rd out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, male rising or falling in Cambodia?
Over the last ten years it is up 60.0%. The long-run trend across the full record is volatile.
Where does this Cambodia data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, male in Cambodia. Statizoid, drawing on UNAIDS estimates. Retrieved 10 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/cambodia/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/cambodia/">Access to anti-retroviral drugs, male in Cambodia</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.